Ingrezza and Austedo Market Share in 2025
Estimates for the 2025 market share of Ingrezza (valbenazine) and Austedo (deutetrabenazine) are not yet available as the year is ongoing and market data is typically compiled and released retrospectively. However, these drugs are key treatments for tardive dyskinesia (TD) and their market performance is influenced by several factors, including patient populations, prescribing patterns, and competition.
What are Ingrezza and Austedo used for?
Ingrezza and Austedo are both approved medications for the treatment of tardive dyskinesia, a movement disorder characterized by involuntary, repetitive movements, most commonly of the face, tongue, lips, jaw, and trunk [1]. Tardive dyskinesia is often a side effect of long-term use of dopamine receptor blocking agents, such as antipsychotics [1].
How do Ingrezza and Austedo work?
Ingrezza works by selectively inhibiting the vesicular monoamine transporter 2 (VMAT2) [2]. This action reduces the amount of dopamine that can be released into the synapse, thereby helping to control the involuntary movements associated with TD [2]. Austedo also targets VMAT2, but it does so with a deuterated form of tetrabenazine, which has a different pharmacokinetic profile [3]. This deuteration is intended to reduce metabolism and prolong the drug's presence in the body, potentially leading to a more consistent effect and fewer dosing adjustments [3].
When do the patents for Ingrezza and Austedo expire?
The patent landscape for both Ingrezza and Austedo is complex and can evolve due to various filings and potential litigation. DrugPatentWatch.com tracks these patents and their expiry dates. For Ingrezza, specific patent expiry dates can be found by searching their database. Similarly, Austedo's patent information is available through similar resources. The patent expiry dates are crucial for determining when generic versions of these drugs may enter the market, which would significantly impact market share [4].
What is the competitive landscape for tardive dyskinesia treatments?
Currently, Ingrezza and Austedo are the primary pharmacological treatments specifically approved for tardive dyskinesia [1]. However, the development of new TD therapies is an active area of research. The market share of Ingrezza and Austedo will be influenced by the emergence of new treatments, the success of off-label uses of other medications, and the potential for biosimilar or generic competition upon patent expiry [4].
How are these drugs prescribed and what are patient concerns?
Prescribing patterns for Ingrezza and Austedo depend on physician familiarity with the medications, patient response, side effect profiles, and insurance coverage. Patient concerns typically revolve around the effectiveness of the treatment in reducing TD symptoms, potential side effects, ease of dosing, and cost. Both drugs aim to improve quality of life for individuals suffering from the often debilitating symptoms of tardive dyskinesia [1].
What are the clinical outcomes and side effects associated with these treatments?
Clinical trials for Ingrezza have demonstrated significant reductions in abnormal involuntary movement scores compared to placebo [2]. Common side effects reported include somnolence, dry mouth, and constipation [2]. Austedo has also shown efficacy in reducing TD symptoms, with reported side effects including depression, parkinsonism, and akathisia [3]. The specific side effect profiles can influence physician prescribing choices and patient adherence.
What is the estimated patient population for tardive dyskinesia?
Estimating the precise patient population for tardive dyskinesia is challenging due to variability in diagnosis and reporting. However, it is understood to affect a significant number of individuals, particularly those on long-term antipsychotic therapy. The increasing awareness of TD and improved diagnostic tools may lead to a larger identified patient pool seeking treatment [1].
What is the pricing and accessibility of Ingrezza and Austedo?
The pricing of specialty medications like Ingrezza and Austedo can be substantial, which can impact patient access and market penetration. Insurance coverage, co-pay assistance programs, and the availability of patient support services play a significant role in determining who can access and afford these treatments [4].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/